Advancing American AI through National Public-Private Partnerships for AI Research
Summary
The Biden-Harris Administration should launch a national initiative to bring together academic and industry researchers and practitioners in a public-private partnership (PPP) to advance, at scale, the research foundations of artificial intelligence (AI) and its application in areas of economic advantage and national need. The National Public-Private Partnership in AI (NPPP-AI) Initiative would initially create 10 coordinated national AI R&D Institutes, each with 10-year lifetimes and jointly funded by industry partners and the U.S. government through its research agencies at $10M/year each (10x10x10).
NPPP-AI would accelerate future breakthroughs in AI foundations, enable a virtuous cycle between foundational and use-inspired research that would rapidly transition into practice innovations that contribute to U.S. economic and national security, as well as grow education and workforce capacity by linking university faculty and students with industry professionals, settings, and jobs.
Given the rapid pace of AI advancement, a proactive effort triumphs over a reactive one. To protect consumers, workers, and the economy more broadly, it is imperative that the FTC and DOJ adapt their enforcement strategies to meet the complexities of the AI era.
To encourage greater adoption of generic drugs in clinical practice the FDA should implement a dedicated regulatory pathway for non-manufacturers to seek approval of new indications for repurposed generic drugs.
By leveraging its substantial purchasing power responsibly, the government can encourage high-quality, inclusive AI solutions that address diverse citizen needs while setting a strong precedent for innovation and accountability.
The federal government should expand the FDA’s priority review voucher program and provide market exclusivity advantages to encourage the development of medications for addiction.